Dosimetric Correlation of Acute Radiation Dermatitis in Patients With Breast Cancer Undergoing Hypofractionated Proton Beam Therapy Using Pencil Beam Scanning

Overview

Journal J Breast Cancer

Date 2024 May 21

PMID 38769685

Authors

Eng-Yen Huang

Meng Wei Ho

Yu-Ming Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: Pencil-beam scanning (PBS) is a modern delivery technique used in proton beam therapy (PBT) to reduce normal tissue reactions. No dosimetric correlation between dermatitis and PBS has been reported for breast cancer. The current study aimed to investigate the factors associated with grade 2 or higher dermatitis in patients with breast cancer undergoing PBT using PBS.

Methods: The medical data of 42 patients with breast cancer who underwent adjuvant radiotherapy between December 2019 and September 2023 were reviewed. All patients received hypofractionated radiotherapy (HFRT), either 26 Gy (relative biological effectiveness [RBE])/five fractions or 40.05 or 43.5 Gy (RBE)/15 fractions, for the whole breast/chest wall with or without nodal irradiation. The duration of acute radiation dermatitis was defined as within 90 days from the start of radiotherapy. The Kaplan-Meier method and Cox proportional hazards model were used for univariate and multivariate analyses of the actuarial rates of grade 2-3 dermatitis.

Results: Twenty-two (52.4%) and 20 (47.6%) patients were diagnosed with grade 1 and 2 dermatitis, respectively. Multivariate analysis revealed a clinical target volume (CTV) ≥ of 320 cc ( = 0.035) and a skin dose of D ≥ 38.3 Gy (RBE) ( = 0.009) as independent factors of grade 2 dermatitis. The 10-week cumulative grade 2 dermatitis rates were 88.2%, 39.4%, and 8.3% ( < 0.001) for patients with both high, either high, and neither high CTV and D, respectively.

Conclusion: To the best of our knowledge, this is the first study on dosimetric correlations for dermatitis in patients with breast cancer who underwent hypofractionated PBT using PBS. In the era of HFRT, skin dose modulation using PBS may reduce the incidence of dermatitis.

References

Luo L, Cuaron J, Braunstein L, Gillespie E, Kahn A, McCormick B . Early outcomes of breast cancer patients treated with post-mastectomy uniform scanning proton therapy. Radiother Oncol. 2018; 132:250-256. DOI: 10.1016/j.radonc.2018.10.002. View

DeCesaris C, Rice S, Bentzen S, Jatczak J, Mishra M, Nichols E . Quantification of Acute Skin Toxicities in Patients With Breast Cancer Undergoing Adjuvant Proton versus Photon Radiation Therapy: A Single Institutional Experience. Int J Radiat Oncol Biol Phys. 2019; 104(5):1084-1090. DOI: 10.1016/j.ijrobp.2019.04.015. View

Bradley J, Dagan R, Wei Ho M, Rutenberg M, Morris C, Li Z . Initial Report of a Prospective Dosimetric and Clinical Feasibility Trial Demonstrates the Potential of Protons to Increase the Therapeutic Ratio in Breast Cancer Compared With Photons. Int J Radiat Oncol Biol Phys. 2015; 95(1):411-421. DOI: 10.1016/j.ijrobp.2015.09.018. View

Cuaron J, Chon B, Tsai H, Goenka A, DeBlois D, Ho A . Early toxicity in patients treated with postoperative proton therapy for locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 2015; 92(2):284-91. PMC: 4972493. DOI: 10.1016/j.ijrobp.2015.01.005. View

Verma V, Iftekaruddin Z, Badar N, Hartsell W, Chang J, Gondi V . Proton beam radiotherapy as part of comprehensive regional nodal irradiation for locally advanced breast cancer. Radiother Oncol. 2017; 123(2):294-298. DOI: 10.1016/j.radonc.2017.04.007. View

Smith N, Jethwa K, Viehman J, Harmsen W, Gonuguntla K, Elswick S . Post-mastectomy intensity modulated proton therapy after immediate breast reconstruction: Initial report of reconstruction outcomes and predictors of complications. Radiother Oncol. 2019; 140:76-83. PMC: 7734651. DOI: 10.1016/j.radonc.2019.05.022. View

Karasawa K, Kunogi H, Hirai T, Hojo H, Hirowatari H, Izawa H . Comparison of hypofractionated and conventionally fractionated whole-breast irradiation for early breast cancer patients: a single-institute study of 1,098 patients. Breast Cancer. 2012; 21(4):402-8. DOI: 10.1007/s12282-012-0406-6. View

Haviland J, Owen J, Dewar J, Agrawal R, Barrett J, Barrett-Lee P . The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013; 14(11):1086-1094. DOI: 10.1016/S1470-2045(13)70386-3. View

Liang X, Li Z, Zheng D, Bradley J, Rutenberg M, Mendenhall N . A comprehensive dosimetric study of Monte Carlo and pencil-beam algorithms on intensity-modulated proton therapy for breast cancer. J Appl Clin Med Phys. 2018; 20(1):128-136. PMC: 6333133. DOI: 10.1002/acm2.12497. View

10.

Hong Z, Yang Z, Mei X, Li P, Bao C, Wang Z . A retrospective study of adjuvant proton radiotherapy for breast cancer after lumpectomy: a comparison of conventional-dose and hypofractionated dose. Radiat Oncol. 2023; 18(1):56. PMC: 10035215. DOI: 10.1186/s13014-023-02213-8. View

11.

Oonsiri P, Nantavithya C, Lertbutsayanukul C, Sarsitthithum T, Vimolnoch M, Tawonwong T . Dosimetric evaluation of photons versus protons in postmastectomy planning for ultrahypofractionated breast radiotherapy. Radiat Oncol. 2022; 17(1):20. PMC: 8799967. DOI: 10.1186/s13014-022-01992-w. View

12.

Thorpe C, Niska J, Anderson J, Girardo M, McGee L, Hartsell W . Acute toxicities after proton beam therapy following breast-conserving surgery for breast cancer: Multi-institutional prospective PCG registry analysis. Breast J. 2020; 26(9):1760-1764. DOI: 10.1111/tbj.13812. View

13.

Tommasino F, Durante M, DAvino V, Liuzzi R, Conson M, Farace P . Model-based approach for quantitative estimates of skin, heart, and lung toxicity risk for left-side photon and proton irradiation after breast-conserving surgery. Acta Oncol. 2017; 56(5):730-736. DOI: 10.1080/0284186X.2017.1299218. View

14.

Bradley J, Wei Ho M, Li Z, Liang X, Rutenberg M, Dagan R . A Technical Guide for Passive Scattering Proton Radiation Therapy for Breast Cancer. Int J Part Ther. 2019; 3(4):473-484. PMC: 6871562. DOI: 10.14338/IJPT-16-00025.1. View

15.

Liang X, Bradley J, Zheng D, Rutenberg M, Yeung D, Mendenhall N . Prognostic factors of radiation dermatitis following passive-scattering proton therapy for breast cancer. Radiat Oncol. 2018; 13(1):72. PMC: 5909216. DOI: 10.1186/s13014-018-1004-3. View

16.

Archambeau J, Pezner R, Wasserman T . Pathophysiology of irradiated skin and breast. Int J Radiat Oncol Biol Phys. 1995; 31(5):1171-85. DOI: 10.1016/0360-3016(94)00423-I. View

17.

Sayan M, Jan I, Vergalasova I, Kilic S, Kumar S, Haffty B . Incidence of clinical lymphedema in breast cancer patients treated with adjuvant proton-based radiotherapy. Rep Pract Oncol Radiother. 2022; 27(3):474-478. PMC: 9518780. DOI: 10.5603/RPOR.a2022.0053. View

18.

Shaitelman S, Schlembach P, Arzu I, Ballo M, Bloom E, Buchholz D . Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol. 2015; 1(7):931-41. PMC: 4635441. DOI: 10.1001/jamaoncol.2015.2666. View

19.

Garda A, Hunzeker A, Michel A, Fattahi S, Shiraishi S, Remmes N . Intensity Modulated Proton Therapy for Bilateral Breast or Chest Wall and Comprehensive Nodal Irradiation for Synchronous Bilateral Breast Cancer: Initial Clinical Experience and Dosimetric Comparison. Adv Radiat Oncol. 2022; 7(3):100901. PMC: 9133394. DOI: 10.1016/j.adro.2022.100901. View

20.

MacDonald S, Patel S, Hickey S, Specht M, Isakoff S, Gadd M . Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2013; 86(3):484-90. DOI: 10.1016/j.ijrobp.2013.01.038. View